Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/3020
Title: Final results of pups a-long study: Evaluating safety and efficacy of rFVIIIFc in previously untreated patients with haemophilia A
Authors: Schiavulli, M.
Brown, S. A.
Liesner, R.
Gunawardena, S.
Carcao, M.
Winding, B.
Jayawardene, D.
Mukhopadhyay, S.
Königs, C.
Ozelo, M. C.
Dunn, A.
Kulkarni, R.
Nolan, B.
Issue Date: 2020
Source: 4, (SUPPL 1), 2020, p. 8
Pages: 8
Journal: Research and Practice in Thrombosis and Haemostasis
Abstract: Background: PUPs A-LONG is the first study evaluating an extended half-life (EHL), recombinant factor VIII Fc fusion protein (rFVIIIFc), in previously untreated patients (PUPs) with haemophilia A. Aims: To evaluate safety, including inhibitor development, and efficacy of rFVIIIFc in PUPs. Methods: This open-label, multicentre, Phase 3 study (NCT02234323) enrolled male PUPs aged <6 years with haemophilia A (<1 IU/dL endogenous FVIII) to receive rFVIIIFc. Primary endpoint was inhibitor development (incidence rate=number of patients with inhibitor/number of patients reaching ≥ 10 exposure days (ED) milestone or with inhibitor). A secondary endpoint was annualized bleeding rate (ABR). Results: Of 103 patients receiving ≥ 1 dose; 80 (77.7%) were <1-year old; 20 (19.4%) had a family history of inhibitors, and 82 (79.6%) had a high-risk haemophilia genotype. Eighty-one patients started on episodic treatment; of these, 69 switched to prophylaxis. Twenty patients started on prophylaxis and 2 were not assigned a regimen. Eighty-seven (84.5%) patients completed the study. Eighty-seven (84.5%), 85 (82.5%), and 81 (78.6%), patients had ≥ 10, ≥20, ≥50 EDs to rFVIIIFc, respectively. Total and high-titre (≥5.00 BU/mL) inhibitor rate was 31.1% (28/90) and 15.6% (14/90), respectively, for patients with ≥ 10 EDs (3 inhibitor patients with <10 EDs included). Median time to inhibitor development was 9 EDs (range: 1-53). rFVIIIFc dosing and efficacy data in Table 1. Twenty-eight (27.2%) had rFVIIIFc treatment-related serious adverse events (TESAEs); FVIII inhibition, n = 28; soft tissue haemorrhage, n = 1; deep vein/CVAD-associated thromboses, n = 2). There was 1 non-treatment- related death due to intracranial haemorrhage (onset during screening period prior to first rFVIIIFc dose). Conclusions: This was the first prospective study of an EHL rFVIIIFc treatment for PUPs with severe haemophilia A. Overall inhibitor development was in the range that can be expected, although high-titre incidence was lower than that reported in the literature. The data demonstrate that rFVIIIFc was well tolerated and effective in this paediatric patient population.L6335466442020-12-07
DOI: 10.1002/rth2.12401
Resources: https://www.embase.com/search/results?subaction=viewrecord&id=L633546644&from=exporthttp://dx.doi.org/10.1002/rth2.12401 |
Keywords: child;clinical trial;conference abstract;controlled study;drug safety;drug therapy;family history;genotype;half life time;hemophilia A;human;incidence;major clinical study;male;recombinant blood clotting factor 8;pediatric patient;phase 3 clinical trial;prophylaxis;prospective study;side effect;soft tissue;thrombosis;vein;fusion protein;blood clotting factor 8endogenous compound;multicenter study;adverse drug reaction;brain hemorrhage
Type: Article
Appears in Sites:Children's Health Queensland Publications

Show full item record

Page view(s)

52
checked on Mar 13, 2025

Google ScholarTM

Check

Altmetric


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.